Breaking News Instant updates and real-time market news.

PFE

Pfizer

$42.97

0.11 (0.26%)

08:58
09/15/18
09/15
08:58
09/15/18
08:58

Pfizer Phase 2a study in alopecia areata met primary, secondary endpoints

Pfizer announced results from its Phase 2a study of PF-06651600, an oral Janus kinase 3 inhibitor, and PF-06700841, a tyrosine kinase 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata, an autoimmune disease characterized by hair loss and often associated with profound psychological consequences. Both JAK inhibitors met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 as measured by the Severity of Alopecia Tool score. The study found that the placebo-adjusted mean in SALT change from baseline scores at Week 24 were 33.6 points for PF-06651600 and 49.5 points for PF-06700841, with statistically significant separation from placebo occurring as early as Week 6 and Week 4, respectively. In addition to meeting the primary efficacy endpoint, the investigational candidates also met all secondary endpoints in this study. "We are pleased with these results and excited by the potential of kinase inhibition as a new therapeutic target for patients living with alopecia areata. This is the first well-controlled study of oral JAK inhibitors in alopecia areata, helping enhance our understanding of this disease with significant unmet need and advance the science of kinase inhibition," said Michael Vincent, M.D, Ph.D., Senior Vice President and Chief Scientific Officer, Pfizer Inflammation and Immunology. Pfizer said that based on the "totality of the data and the emerging clinical profiles," the investigational JAK3 inhibitor, which was recently granted Breakthrough Therapy designation from FDA for alopecia areata, is advancing to the next phase of development for moderate to severe alopecia areata and will continue to be evaluated for rheumatoid arthritis, Crohn's disease and ulcerative colitis. PF-06700841 will continue to be evaluated for psoriasis, CD and UC.

  • 26

    Sep

  • 01

    Oct

  • 10

    Oct

  • 17

    Oct

  • 22

    Oct

PFE Pfizer
$42.97

0.11 (0.26%)

09/06/18
BOFA
09/06/18
NO CHANGE
Target $92
BOFA
Buy
Exact Sciences price target raised to $92 post Pfizer deal at BofA/Merrill
BofA/Merrill analyst Derik de Bruin said Exact Sciences (EXAS) co-promotion agreement for Cologuard with Pfizer (PFE) adds significant "marketing muscle" to the company's strong fundamental story. The deal will help Exact Sciences penetrate healthcare systmes and allow the company to increase its advertising and promotional spect through better rates by utilizing Pfizer's purchasing power, the analyst wrote in a note to investors. de Bruin reiterates his Buy rating on Exact Sciences and increased his price target to $92 from $68 on shares.
09/06/18
BMOC
09/06/18
NO CHANGE
Target $47
BMOC
Outperform
Pfizer price target raised to $47 from $44 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Pfizer to $47 and kept his Outperform rating, citing the company's Tafamidis potential prospects of $3.5B or more in sales by 2027. The analyst notes that Transthyretin Amyloid Cardiomyopathy, or ATTR-CM, is a "fatal, under-diagnosed heart disease with no approved treatments", but the new method of diagnosis could ramp up from 1% to 20%, supporting the "robust efficacy" with "benign safety" offered by the company's treatment. Arfaei further contends that Pfizer's 3.5% dividend yield and 14-times forward earnings multiple make the stock attractive.
09/11/18
BARD
09/11/18
NO CHANGE
Target $85
BARD
Outperform
Exact Sciences price target raised to $85 from $74 at Baird
Baird analyst Catherine Ramsey Schulte raised her price target on Exact Sciences (EXAS) to $85 from $74 citing increased confidence in its partnership with Pfizer (PFE). She sees several different potential outcomes given different assumptions for Pfizer rep productivity and order rate increases. Schulte reiterated her Outperform rating on Exact Sciences shares.
09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.

TODAY'S FREE FLY STORIES

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

18:01
09/21/18
09/21
18:01
09/21/18
18:01
Hot Stocks
Johnson & Johnson's Janssen discloses phase 3 study results of Esketamine »

The Janssen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 28

    Oct

UAL

United Continental

$89.94

0.8 (0.90%)

17:39
09/21/18
09/21
17:39
09/21/18
17:39
Periodicals
United pilots refuse contract changes on regional routes, Reuters says »

United Airlines pilots…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

, XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

17:36
09/21/18
09/21
17:36
09/21/18
17:36
General news
Week ending ETF Scorecard: Materials outperform, Utlilites slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.11

0.5132 (0.69%)

XLU

Utilities SPDR

$53.04

0.2049 (0.39%)

IYR

DJ US Real Estate Index Fund

$81.88

-0.06 (-0.07%)

XLP

Consumer Staples Sector SPDR

$55.02

0.1285 (0.23%)

XLY

Consumer Discretionary Sector SPDR

$116.98

-0.4288 (-0.37%)

XLB

S&P Select Materials SPDR

$60.54

-0.1312 (-0.22%)

XLF

Financial Select Sector

$28.73

-0.1175 (-0.41%)

XLV

Health Care Select Sector SPDR

$94.26

0.1571 (0.17%)

XLK

Technology Select Sector SPDR

$74.68

-0.2056 (-0.27%)

XLI

Industrial Select Sector SPDR

$79.71

0.2338 (0.29%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

SLV

iShares Silver Trust

$13.44

-0.01 (-0.07%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

UNG

United States Natural Gas Fund

$24.60

0.235 (0.96%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.24

0.05 (0.06%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.72

0.04 (0.03%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.12

-0.02 (-0.02%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.00

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.05

0.02 (0.02%)

IWD

iShares Russell 1000 Value

$129.51

0.13 (0.10%)

IWF

iShares Russell 1000 Growth

$155.30

-0.55 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHGI

One Horizon Group

$0.18

-0.0088 (-4.63%)

17:34
09/21/18
09/21
17:34
09/21/18
17:34
Syndicate
Breaking Syndicate news story on One Horizon Group »

One Horizon Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.41

-0.033 (-7.38%)

17:31
09/21/18
09/21
17:31
09/21/18
17:31
Syndicate
Breaking Syndicate news story on Cytori Therapeutics »

Cytori Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$31.56

0.05 (0.16%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Syndicate
Breaking Syndicate news story on Newmont Mining »

Newmont Mining files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Oct

CB

Chubb

$139.87

-0.05 (-0.04%)

17:22
09/21/18
09/21
17:22
09/21/18
17:22
Hot Stocks
Chubb CEO Greenberg sells $8.6M in common stock »

Chubb CEO Evan Greenberg…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTVT

vTv Therapeutics

$0.80

0.0096 (1.21%)

17:21
09/21/18
09/21
17:21
09/21/18
17:21
Hot Stocks
vTv says FDA advised that azeliragon efficacy be shown in at least 2 trials »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VYGR

Voyager Therapeutics

$18.21

-0.27 (-1.46%)

17:17
09/21/18
09/21
17:17
09/21/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Voyager Therapeutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNRC

Generac

$57.99

-0.02 (-0.03%)

17:16
09/21/18
09/21
17:16
09/21/18
17:16
Hot Stocks
Generac announces new $250M share repurchase program »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

, IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Conference/Events
Independent Bank to host special shareholder meeting »

Special Shareholder…

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

HRS

Harris

$164.33

1.685 (1.04%)

17:13
09/21/18
09/21
17:13
09/21/18
17:13
Hot Stocks
Harris awarded $255.4M Department of Defense contract »

Harris Corp has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMBC

Pacific Mercantile Bancorp

$9.25

-0.5 (-5.13%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Pacific Mercantile Bancorp »

FJ Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

WSC

WillScot

$17.10

-0.05 (-0.29%)

17:10
09/21/18
09/21
17:10
09/21/18
17:10
Syndicate
Breaking Syndicate news story on WillScot »

WillScot files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$2.50

-0.9 (-26.47%)

17:09
09/21/18
09/21
17:09
09/21/18
17:09
Hot Stocks
Breaking Hot Stocks news story on DAVIDsTEA »

TDM Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$23.45

0.3 (1.30%)

, EXPE

Expedia

$133.73

-0.77 (-0.57%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Hot Stocks
Expedia president Bhutani joins New York Times board »

The New York Times…

NYT

New York Times

$23.45

0.3 (1.30%)

EXPE

Expedia

$133.73

-0.77 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

, GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

17:08
09/21/18
09/21
17:08
09/21/18
17:08
Conference/Events
Guaranty Bancorp to host special shareholder meeting »

Special Shareholder…

IBTX

Independent Bank

$67.60

-1.15 (-1.67%)

GBNK

Guaranty Bancorp

$30.20

-0.5 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

, ANDV

Andeavor

$154.80

2.19 (1.44%)

17:01
09/21/18
09/21
17:01
09/21/18
17:01
Conference/Events
Andeavor to host special shareholder meeting »

Special Shareholder…

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

ANDV

Andeavor

$154.80

2.19 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

ANDV

Andeavor

$154.80

2.19 (1.44%)

, MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

16:59
09/21/18
09/21
16:59
09/21/18
16:59
Conference/Events
Marathon Petroleum to host special shareholder meeting »

Special Shareholder…

ANDV

Andeavor

$154.80

2.19 (1.44%)

MPC

Marathon Petroleum

$83.37

1.44 (1.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

EPRT

Essential Properties Realty Trust

$14.49

-0.015 (-0.10%)

16:45
09/21/18
09/21
16:45
09/21/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Essential Properties Realty Trust »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBSI

Barrett Business

$63.67

0.04 (0.06%)

16:43
09/21/18
09/21
16:43
09/21/18
16:43
Hot Stocks
SEC says Barrett Business to pay $1.5M penalty over improper accounting »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGA

Siga Technologies

$7.25

0.5 (7.41%)

16:42
09/21/18
09/21
16:42
09/21/18
16:42
Conference/Events
Siga Technologies to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

SPY

SPDR S&P 500 ETF Trust

$292.03

-0.1774 (-0.06%)

, USO

United States Oil Fund

$14.95

0.145 (0.98%)

16:36
09/21/18
09/21
16:36
09/21/18
16:36
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 0.1K…

SPY

SPDR S&P 500 ETF Trust

$292.03

-0.1774 (-0.06%)

USO

United States Oil Fund

$14.95

0.145 (0.98%)

GLD

SPDR Gold Trust

$113.48

-0.77 (-0.67%)

FXE

Euro Currency Trust

$112.55

-0.27 (-0.24%)

FXC

CurrencyShares Canadian Dollar Trust

$76.37

-0.09 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMCF

Emclaire Financial

$37.90

0.84 (2.27%)

16:36
09/21/18
09/21
16:36
09/21/18
16:36
Hot Stocks
Emclaire Financial announces shareholder, regulatory approval of merger »

Emclaire Financial and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

16:32
09/21/18
09/21
16:32
09/21/18
16:32
Conference/Events
Roche to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.